



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On

TOWNSEND and TOWNSEND and CREW LLP

By:

**AMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE –
EXAMINING GROUP 1647**

PATENT

Attorney Docket No.: 080421-000100US

Client Ref. No.: 80021-255

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

TUDAN *et al.*

Application No.: 10/086,177

Filed: February 26, 2002

For: CXC CHEMOKINE RECEPTOR 4
AGONIST PEPTIDES

Confirmation No. 1250

Examiner: Bunner, Bridget E.

Art Unit: 1647

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE EXAMINING
GROUP 1647

Mail Stop AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

This Amendment is responsive to the Final Office Action mailed October 12, 2005, on the above-referenced application. A Notice of Appeal was filed on March 13, 2006. Applicants believe that no fee is required for submission of this response. However if a fee is required, the Commissioner is authorized to deduct such a fee from the undersigned's Deposit Account No. 20-1430.

Appl. No. 10/086,177

PATENT

Amdt. dated July 24, 2006

Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1647

In order to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing.

Please enter and consider the following amendments and remarks:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 40 of this paper.

Remarks/Arguments begin on page 41 of this paper.